Anti-IL-6 Antibody Binding Specificity for Therapeutic Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compositions and methods that can effectively prevent or treat diseases associated with Interleukin-6 (IL-6) while minimizing adverse reactions, and for methods to screen for patients with IL-6-related diseases.
Innovation Solution
Development of an anti-IL-6 antibody with specific amino acid sequences for its light and heavy chains, which binds to IL-6 or IL-6/IL-6R/gp130 complexes, inhibiting their biological effects, and can be used for diagnosis and treatment of IL-6-related disorders, including cancer-associated fatigue and rheumatoid arthritis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-IL-6 antibodies are administered to treat IL-6-related diseases, then therapeutic efficacy is improved, but adverse reactions may occur
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody's binding affinity (KD < 50 picomolar) and selecting specific amino acid sequences in the CDR regions to enhance therapeutic efficacy while reducing adverse reactions. The constant heavy chain domain is specifically selected to modulate effector functions and minimize immunogenicity
Solution Approach 2:
The patent applies local quality by engineering specific regions of the antibody with distinct properties: the variable regions are optimized for high-affinity IL-6 binding, while the constant regions are selected to control effector functions and reduce adverse effects, creating localized functional optimization throughout the antibody structure
2Reliability
If high affinity binding to IL-6 is achieved, then inhibition of IL-6 biological effects is improved, but antibody complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into distinct functional modules: variable regions (VL and VH) are engineered for high-affinity binding with specific CDR sequences, while constant regions (CL and CH) are selected to provide structural stability and controlled effector functions. This modular design achieves high binding affinity without excessive overall complexity
Solution Approach 2:
The patent applies universality by designing an antibody structure that performs multiple functions: the variable regions bind IL-6 with high affinity, the constant regions provide structural stability, and the overall structure enables both neutralization of IL-6 and modulation of immune responses, achieving multifunctionality with a single molecular entity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-IL-6 antibody effectively binds to IL-6 with a dissociation constant of less than 50 picomolar, inhibiting IL-6 biological effects, and is suitable for treating and preventing IL-6-related diseases with minimal adverse reactions, as demonstrated by its use in various assays and clinical applications.
Implementation Method 1
the antibody has a dissociation constant (KD) of less than 50 picomolar as assessed by BIAcore. This antibody may bind soluble IL-6 or cell surface expressed IL-6
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is directed to antibodies and fragments thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.